ADCX-020

ADCX-020 is an antibody-drug conjugate from Adcytherix. An antibody-drug conjugate; the company says its ADCs pair clinically validated targets with payloads derived from approved cancer drugs, but has not disclosed ADCX-020's target or payload. Its furthest stage is phase 1, for locally advanced or metastatic solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1a/b NCT07238075 recruiting; started 23 February 2026. Whether it works in people has not been established unless a trial below reports it.